COVID-19: Bharat Biotech's Covaxin gets nod for phase three trial; 22,000 volunteers enrolled
October 23, 2020
105
3
4
6.67%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Mirror Now Episodes Around October 23, 2020
See what was published immediately before and after this episode.
2:41Now PlayingCOVID-19: Bharat Biotech's Covaxin gets nod for phase three trial; 22,000 volunteers enrolled
YouTube Description
as posted by the channelBharat biotech's Covaxin gets a nod for its phase three trials in India. The vaccine is created by ICMR and Bharat Biotech and the permission for phase three clinical trials has been granted.
According to the sources, 22,000 volunteers have enrolled for the trial and the trials will be conducted in almost 18-19 sites. The trials of the first two phases were conducted at 12 sites across India and the trials were conducted for almost 2 months. This is the first indigenous vaccine of India which is going for the clinical trials. The clinical trials of Covaxin are likely to begin in November.
SUBSCRIBE NOW for more such videos ►
For More Updates ►
Like us on Facebook ►
Follow us on Twitter ►
Follow us on Instagram ►
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.